Shares of Exact Sciences (EXAS) - Get Report were gaining by 7.12% to $22.61  early Monday afternoon following a decision by insurance provider Aetna (AET) to offer commercial coverage of the molecular diagnostics company's Cologuard test.

Cologuard is the first FDA approved stool-based DNA screening test for colon cancer. The test is already covered under Aetna's Medicare plan.

With this Cologuard's coverage is expanded to about 190MM lives, Cowen wrote in a note today, according to Barron's.